Outcome Measures in ANCA-associated Vasculitis

Rheumatic Disease Clinics of North America

Volumn 36, Issue 3, 2010, Pages 587-607

  Suppiah, Ravi ^a   Robson, Joanna ^a   Luqmani, Raashid ^a  

^a NUFFIELD ORTHOPAEDIC CENTRE   (United Kingdom)

Author keywords

Birmingham Vasculitis Activity Score; Combined Damage Assessment Index; Outcome measures; Patient reported outcome measures; Vasculitis; Vasculitis Damage Index

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; ETANERCEPT; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; PLACEBO; RITUXIMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ANCA ASSOCIATED VASCULITIS; ANTIBODY TITER; BIRMINGHAM VASCULITIS ACTIVITY SCORE; CHURG STRAUSS SYNDROME; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE EXTENT INDEX; DISEASE SEVERITY; DRUG ADMINISTRATION ROUTE; DRUG HYPERSENSITIVITY; DRUG PULSE THERAPY; DRUG SAFETY; FIVE FACTOR SCORE; FRENCH VASCULITIS STUDY GROUP; HEALTH ASSESSMENT QUESTIONNAIRE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LEUKOPENIA; MALIGNANT NEOPLASTIC DISEASE; MICROSCOPIC POLYANGIITIS; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RELAPSE; REMISSION; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SHORT FORM 36; TREATMENT RESPONSE; VASCULITIS DAMAGE INDEX; WEGENER GRANULOMATOSIS;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; HUMANS; RECOVERY OF FUNCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77955238740     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2010.04.001     Document Type: Review

References (78)

1. Davson J., Ball J., Platt R. The kidney in periarteritis nodosa. Q J Med 1948, 17(67):175-202.
2. Fahey J.L., Leonard E., Churg J., et al. Wegener's granulomatosis. Am J Med 1954, 17(2):168-179.
3. Godman G.C., Churg J. Wegener's granulomatosis: pathology and review of the literature. AMA Arch Pathol 1954, 58(6):533-553.
4. Hollander D., Manning R.T. The use of alkylating agents in the treatment of Wegener's granulomatosis. Ann Intern Med 1967, 67(2):393-398.
5. Hoffman G.S., Kerr G.S., Leavitt R.Y., et al. Wegener's granulomatosis: an analysis of 158 patients. Ann Intern Med 1992, 116(6):488-498.
6. Bligny D., Mahr A., Toumelin P.L., et al. Predicting mortality in systemic Wegener's granulomatosis: a survival analysis based on 93 patients. Arthritis Rheum 2004, 51(1):83-91.
7. Bourgarit A., Le Toumelin P., Pagnoux C., et al. Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine (Baltimore) 2005, 84(5):323-330.
8. Burkhardt O., Kohnlein T., Wrenger E., et al. Predicting outcome and survival in patients with Wegener's granulomatosis treated on the intensive care unit. Scand J Rheumatol 2007, 36(2):119-124.
9. de Groot K., Harper L., Jayne D.R., et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009, 150(10):670-680.
10. de Groot K., Rasmussen N., Bacon P.A., et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005, 52(8):2461-2469.
11. Jayne D., Rasmussen N., Andrassy K., et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003, 349(1):36-44.
12. Jayne D.R., Gaskin G., Rasmussen N., et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007, 18(7):2180-2188.
13. Hoffman G.S., Drucker Y., Cotch M.F., et al. Wegener's granulomatosis: patient-reported effects of disease on health, function, and income. Arthritis Rheum 1998, 41(12):2257-2262.
14. Koutantji M., Harrold E., Lane S.E., et al. Investigation of quality of life, mood, pain, disability, and disease status in primary systemic vasculitis. Arthritis Rheum 2003, 49(6):826-837.
15. Guillevin L., Jarrousse B., Lok C., et al. Longterm followup after treatment of polyarteritis nodosa and Churg-Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange. A prospective randomized trial of 71 patients. The Cooperative Study Group for Polyarteritis Nodosa. J Rheumatol 1991, 18(4):567-574.
16. Guillevin L., Lhote F., Gayraud M., et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 1996, 75(1):17-28.
17. Metzler C., Hellmich B., Gause A., et al. Churg Strauss syndrome-successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin Exp Rheumatol 2004, 22(6 Suppl 36):S52-S61.
18. Stegeman C.A., Tervaert J.W., Sluiter W.J., et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener's granulomatosis. Ann Intern Med 1994, 120(1):12-17.
19. de Groot K., Muhler M., Reinhold-Keller E., et al. Induction of remission in Wegener's granulomatosis with low dose methotrexate. J Rheumatol 1998, 25(3):492-495.
20. Koldingsnes W., Nossent J.C. Baseline features and initial treatment as predictors of remission and relapse in Wegener's granulomatosis. J Rheumatol 2003, 30(1):80-88.
21. Stegeman C.A., Tervaert J.W., de Jong P.E., et al. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener's Study Group. N Engl J Med 1996, 335(1):16-20.
22. Mahr A., Girard T., Agher R., et al. Analysis of factors predictive of survival based on 49 patients with systemic Wegener's granulomatosis and prospective follow-up. Rheumatology (Oxford) 2001, 40(5):492-498.
23. Fain O., Hamidou M., Cacoub P., et al. Vasculitides associated with malignancies: analysis of sixty patients. Arthritis Rheum 2007, 57(8):1473-1480.
24. Faurschou M., Mellemkjaer L., Sorensen I.J., et al. Increased morbidity from ischemic heart disease in patients with Wegener's granulomatosis. Arthritis Rheum 2009, 60(4):1187-1192.
25. Faurschou M., Sorensen I.J., Mellemkjaer L., et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 2008, 35(1):100-105.
26. Guillevin L, Pagnoux C, Mahr A, et al. The five factor score (FFS) revisited: a tool to assess the prognoses of polyarteritis nodosa (PAN), microscopic polyangiitis (MPA), Churg-Strauss syndrome (CSS) and Wegener's granulomatosis (WG) based on 1108 patients from the French Vasculitis Study Group [abstract]. American College of Rheumatology Annual Scientific Conference 2008 Available at:, Accessed December 9, 2009. http://acr.confex.com/acr/2008/webprogram/Paper2220.html.
27. Koldingsnes W., Nossent H. Predictors of survival and organ damage in Wegener's granulomatosis. Rheumatology (Oxford) 2002, 41(5):572-581.
28. Aasarod K., Iversen B.M., Hammerstrom J., et al. Wegener's granulomatosis: clinical course in 108 patients with renal involvement. Nephrol Dial Transplant 2000, 15(12):2069.
29. Reinhold-Keller E., Beuge N., Latza U., et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000, 43(5):1021-1032.
30. Phillip R., Luqmani R. Mortality in systemic vasculitis: a systematic review. Clin Exp Rheumatol 2008, 26(5 Suppl 51):S94-104.
31. Mukhtyar C., Lee R., Brown D., et al. Modification and validation of the Birmingham vasculitis activity score (version 3). Ann Rheum Dis 2009, 68(12):1827-1832.
32. Finkielman J.D., Merkel P.A., Schroeder D., et al. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener's granulomatosis. Ann Intern Med 2007, 147(9):611-619.
33. Falk R.J., Jennette J.C. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 1988, 318(25):1651-1657.
34. van der Woude F.J., Rasmussen N., Lobatto S., et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985, 1(8426):425-429.
35. Boomsma M.M., Stegeman C.A., van der Leij M.J., et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 2000, 43(9):2025-2033.
36. Gaskin G., Savage C.O., Ryan J.J., et al. Anti-neutrophil cytoplasmic antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis. Nephrol Dial Transplant 1991, 6(10):689-694.
37. Hogan S.L., Falk R.J., Chin H., et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 2005, 143(9):621-631.
38. Sanders J.S., Huitma M.G., Kallenberg C.G., et al. Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment. Rheumatology (Oxford) 2006, 45(6):724-729.
39. Slot M.C., Tervaert J.W., Boomsma M.M., et al. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum 2004, 51(2):269-273.
40. Terrier B., Saadoun D., Sene D., et al. Antimyeloperoxidase antibodies are a useful marker of disease activity in antineutrophil cytoplasmic antibody-associated vasculitides. Ann Rheum Dis 2009, 68(10):1564-1571.
41. Tomasson G., Grayson P., Mahr A., et al. The value of rise in anti-neutrophil cytoplasmic antibody (ANCA) measurements for predicting relapse among patients with ANCA-associated vasculitis - a meta-analysis. Arthritis Rheum 2009, 60(Suppl 10):648. [abstract].
42. Han W.K., Choi H.K., Roth R.M., et al. Serial ANCA titers: useful tool for prevention of relapses in ANCA-associated vasculitis. Kidney Int 2003, 63(3):1079-1085.
43. Tervaert J.W., Huitema M.G., Hene R.J., et al. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 1990, 336(8717):709-711.
44. De'Oliviera J., Gaskin G., Dash A., et al. Relationship between disease activity and anti-neutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis. Am J Kidney Dis 1995, 25(3):380-389.
45. Girard T., Mahr A., Noel L.H., et al. Are antineutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener's granulomatosis? A prospective study. Rheumatology (Oxford) 2001, 40(2):147-151.
46. Kerr G.S., Fleisher T.A., Hallahan C.W., et al. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis. Arthritis Rheum 1993, 36(3):365-371.
47. Kallenberg C.G., Tervaert J.W., Stegeman C.A. Criteria for disease activity in Wegener's granulomatosis: a requirement for longitudinal clinical studies. APMIS Suppl 1990, 19:37-39.
48. Whiting-O'Keefe Q.E., Stone J.H., Hellmann D.B. Validity of a vasculitis activity index for systemic necrotizing vasculitis. Arthritis Rheum 1999, 42(11):2365-2371.
49. Flossmann O., Bacon P., de Groot K., et al. Development of comprehensive disease assessment in systemic vasculitis. Ann Rheum Dis 2007, 66(3):283-292.
50. Hellmich B., Flossmann O., Gross W.L., et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007, 66(5):605-617.
51. Luqmani R.A., Bacon P.A., Moots R.J., et al. Birmingham vasculitis activity score (BVAS) in systemic necrotizing vasculitis. QJM 1994, 87(11):671-678.
52. WGET Study Group Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005, 352(4):351-361.
53. Booth A., Harper L., Hammad T., et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004, 15(3):717-721.
54. Metzler C., Miehle N., Manger K., et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford) 2007, 46(7):1087-1091.
55. Stone J.H., Hoffman G.S., Merkel P.A., et al. A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham vasculitis activity score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum 2001, 44(4):912-920.
56. de Groot K., Adu D., Savage C.O. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 2001, 16(10):2018-2027.
57. Merkel P.A., Cuthbertson D.D., Hellmich B., et al. Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. Ann Rheum Dis 2009, 68(1):103-106.
58. Merkel P.A., Herlyn K., Mahr A.D., et al. Progress towards a core set of outcome measures in small-vessel vasculitis. Report from OMERACT 9. J Rheumatol 2009, 36(10):2362-2368.
59. Mukhtyar C., Lee R., Brown D., et al. Modification and validation of the Birmingham vasculitis activity score (version 3). Ann Rheum Dis 2009, 68(12):1827-1832.
60. Gayraud M., Guillevin L., le Toumelin P., et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001, 44(3):666-675.
61. Seo P., Min Y.I., Holbrook J.T., et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's granulomatosis etanercept trial (WGET). Arthritis Rheum 2005, 52(7):2168-2178.
62. Jones R., Cohen Tevaert J., Hauser T., et al. Randomized trial of rituximab vs cyclophosphamide for ANCA-associated renal vasculitis: RITUXVAS [abstract]. APMIS 2009, 117(Suppl 127):78.
63. Exley A.R., Bacon P.A., Luqmani R.A., et al. Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997, 40(2):371-380.
64. Bacon P.A., Moots R.J., Exley A., et al. VITAL (vasculitis integrated assessment log) assessment of vasculitis. Clin Exp Rheumatol 1995, 13(2):275-278.
65. Abu-Shakra M., Smythe H., Lewtas J., et al. Outcome of polyarteritis nodosa and Churg-Strauss syndrome. An analysis of twenty-five patients. Arthritis Rheum 1994, 37(12):1798-1803.
66. Exley A.R., Carruthers D.M., Luqmani R.A., et al. Damage occurs early in systemic vasculitis and is an index of outcome. QJM 1997, 90(6):391-399.
67. Seo P., Luqmani R.A., Flossmann O., et al. The future of damage assessment in vasculitis. J Rheumatol 2007, 34(6):1357-1371.
68. Seo P., Jayne D., Luqmani R., et al. Assessment of damage in vasculitis: expert ratings of damage. Rheumatology (Oxford) 2009, 48(7):823-827.
69. Suppiah R., Flossmann O., Mukhtyar C., et al. A cross sectional study comparing the CDA to the VDI for the assessment of damage in vasculitis. Arthritis Rheum 2009, 60(Suppl 10):644. [abstract].
70. Boomsma M.M., Bijl M., Stegeman C.A., et al. Patients' perceptions of the effects of systemic lupus erythematosus on health, function, income, and interpersonal relationships: a comparison with Wegener's granulomatosis. Arthritis Rheum 2002, 47(2):196-201.
71. Reinhold-Keller E., Herlyn K., Wagner-Bastmeyer R., et al. Effect of Wegener's granulomatosis on work disability, need for medical care, and quality of life in patients younger than 40 years at diagnosis. Arthritis Rheum 2002, 47(3):320-325.
72. McHorney C.A., Ware J.E., Rogers W., et al. The validity and relative precision of MOS short- and long-form health status scales and Dartmouth COOP charts. Results from the medical outcomes study. Med Care 1992, 30(Suppl 5):MS253-MS265.
73. Fries J.F., Spitz P.W., Young D.Y. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982, 9(5):789-793.
74. Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983, 67(6):361-370.
75. Botteman M.F., Hay J.W., Luo M.P., et al. Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom. Rheumatology (Oxford) 2007, 46(8):1320-1328.
76. McLeod C., Bagust A., Boland A., et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess 2007, 11(28):1-158. iii-iv.
77. Smith N., Ding T., Butt S., et al. The importance of the baseline disease activity score 28 in determining responders and non-responders to anti-TNF in UK clinical practice. Rheumatology (Oxford) 2008, 47(9):1389-1391.
78. Smith N., Gadsby K., Butt S., et al. Is pre-assessment for anti-TNF therapy in RA necessary in the UK? Analysis of DAS28 in six centres. Rheumatology (Oxford) 2007, 46(10):1557-1559.